Table 1.
Demographic, clinical, biological, and pathological findings at the time of idiopathic nephrotic syndrome
| Total population |
Remission |
No remission |
P value | |
|---|---|---|---|---|
| n = 21 | n = 7 | n = 14 | ||
| Clinical data | ||||
| Age (y) [IQR] | 34 [20–49] | 50 [31–52] | 26 [19–38] | 0.03 |
| Min-Max (y) | 16–76 | 16–76 | 16–49 | |
| Men (%) | 14 (66.7) | 6 (85.7) | 8 (57.1) | 0.41 |
| African ancestry (%) | 3 (14.3) | 2 (28.6) | 1 (7.1) | 0.51 |
| Body mass index (kg/m2) [IQR]; n = 19/21, 6/7, 13/14 | 23.8 [21.6–26.9] | 25.1 [23.3–27.5] | 23.4 [21.3–26.5] | 0.32 |
| - < 25 (%) | 11 (57.9) | 3 (50) | 8 (61.5) | |
| - 25–29.9 (%) | 8 (42) | 3 (50) | 5 (38.5) | |
| - ≥ 30 (%) | 0 | 0 | 0 | |
| Comorbid conditions | ||||
| - Hypertension (%) | 2 (9.5) | 1 (14.3) | 1 (7.1) | |
| - History of atopic disease (%) | 2 (9.5) | 1 (14.3) | 1 (7.1) | |
| Renal parameters | ||||
| Systolic blood pressure (mm Hg) [IQR]; n = 18/21, 6/7, 12/14 | 140 [126–155] | 144 [127–161] | 140 [123–153] | 0.67 |
| Diastolic blood pressure (mm Hg) [IQR]; n = 18/21, 6/7, 12/14 | 80 [75–91] | 88 [74–101] | 80 [75–90] | 0.47 |
| Serum albumin level (g/l) [IQR] | 19.0 [14.8–23.0] | 19.0 [11.2–28.0] | 18.1 [14.9–21.2] | 0.45 |
| Proteinuria (g/d) [IQR] | 10.0 [5.1–10.2] | 10.0 [5.0–16.5] | 8.4 [5.1–10.1] | 0.27 |
| Serum creatinine (μmol/l) [IQR] | 93 [77–115] | 110 [80–137] | 86 [74–107] | 0.14 |
| eGFR (mL/min per 1.73 m2) [IQR] | 80 [65–106] | 66 [50–83] | 91 [68–111] | 0.09 |
| Acute kidney injury (AKI)a (%) | 5 (23.8) | 3 (42.9) | 2 (14.3) | 0.37 |
| - AKI stage 1 (%) | 4 (19.1) | 2 (28.6) | 2 (14.3) | |
| - AKI stage 2 (%) | 0 | 0 | 0 | |
| - AKI stage 3 (%) | 1 (4.8) | 1 (14.3) | 0 | |
| Renal biopsy findings | ||||
| Focal segmental glomerulosclerosis (%) | 12 (57.1) | 4 (57.1) | 8 (57.1) | 1 |
| Minimal change nephrotic syndrome (%) | 9 (42.9) | 3 (42.9) | 6 (42.9) | 1 |
| Steroid-resistant nephrotic syndrome (SRNS) (%) | 19 (90.5) | 6 (85.7) | 13 (92.9) | 1 |
| Steroid-dependent nephrotic syndrome (SDNS) (%) | 2 (9.5) | 1 (14.3) | 1 (7.1) | 1 |
| Genetic analysis n = 9/19 | ||||
| Targeted sequencing of genes involved in SRNS (%) | 9 (47.4) | 2 (33.3) | 7 (53.9) | 0.4 |
| Negative for monogenic mutation in SRNS genes (%) | 9 (47.4) | 2 (33.3) | 7 (53.9) | 0.4 |
| Positive for high-risk polymorphism apolipoprotein L1 genotypesb (%) | 2 (10.5) | 1 (16.7) | 1 (7.7) | 0.55 |
| Not performed (%) | 10 (52.6) | 4 (66.7) | 6 (46.1) | 0.4 |
Qualitative data are expressed as n (%), quantitative data as median [interquartile range; IQR], as appropriate.
Glomerular filtration rate (GFR) was estimated (eGFR) by the Chronic Kidney Disease Epidemiology Collaboration equation.
a
Acute kidney injury was defined according to Kidney Disease Improving Global Outcomes (KDIGO) criteria
b
High-risk apolipoprotein L1 genotypes were defined as 2 risk alleles in any combination (homozygous G1/G1, homozygous G2/G2, or compound heterozygous G1/G2).